-
Trump renames AI "super intelligence," rejects international oversight
-
Moldova declares energy, water emergency
-
Trump rejects international regulation of AI
-
French Holocaust denier jailed for eight months
-
How is the EU approaching record fuel prices?
-
Oil prices slide, AI stock buzz fades
-
Sri Lanka's Colombage strikes on debut as England dismissed for 265 in first ODI
-
Trump threatens to 'annihilate' Iran in bombastic UN speech
-
Hurricane Polo strengthens to top category 5 off Mexico
-
Prada's skirts take centre stage as Milan Fashion Week begins
-
11 hurt as teen opens fire outside school in western Turkey
-
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
-
UN chief says 'Big Oil' treats atmosphere as open sewer
-
Brazil's Flavio Bolsonaro turns scandal into poll gains
-
Tunisia says 2026 summer hottest on record
-
Republican senator seeks probe of Trump Jr Russian-funded wedding
-
England's Rashid out of Sri Lanka ODIs with hand injury
-
Memoir by Diana's brother goes on sale after rocking UK monarchy
-
Houthis accuse Saudi Arabia of deadly strikes as thousands flee
-
Newcomers South Korea face holders Italy in Davis Cup finals
-
Stocks climb as oil slides, AI buzz returns
-
Japan's Kojima sounds Marchand warning with Asian Games gold
-
India cricketers win in style as Afghan savours 'special' Games silver
-
England rugby star Pollock signs new Northampton deal
-
La Liga president hits out at Real Madrid refereeing 'conspiracy' claims
-
STARTRADER Expands Its Chinese Equity CFD Range with CXMT and Unitree Robotics
-
MEXC Launches “Real Stocks, Real Friends” with Rewards for Bringing Friends to Wall Street
-
MEXC Expands Opportunity Compass with Stock Trading Handbook to Help Crypto Users Build Investment Knowledge
-
Mbappe continues media push for Ballon d'Or recognition
-
England paceman Wood retires from international cricket
-
Stocks rise on AI buzz, oil prices cool
-
Magnificent Mandhana's 79 helps India to Asian Games cricket gold
-
India narrowly survive huge scare against minnows Japan
-
Marchand 'stressed' about racing Japanese rivals at LA Olympics
-
Missing F-35 fighter parts 'not sensitive', says Australia minister
-
Mobile boat clinics bring healthcare to India's remote islands
-
Cambodia showcases scams crackdown with global conference
-
Former India paceman Zaheer Khan named Chennai coach in IPL
-
Afghan cyclist who disguised herself as man wins Asian Games silver
-
Six-year-old Chinese girl sets world record with Rubik's Cube
-
Typhoon Dujuan leaves four dead in Japan, 45,000 houses without power
-
Swimming prodigy Yu, 13, says 'interviews way harder than racing'
-
G7 leaders condemn Houthi strikes on Saudi Arabia
-
Star coaches make their bows as Nations League returns
-
Google data centre sparks protests in Austria
-
Rams bounce back as Giants reel from Dart injury
-
Shin Ohashi: Junk food-loving teen and Japan's next big swimming hope
-
In Bangladesh, Pakistan's Jinnah photo stirs anger
-
Stocks rise on AI buzz, drop in oil prices
-
Two New Zealand naval ships transit Taiwan Strait
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
S.Gantenbein--VB